Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04054206 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers
A Phase 1 study, sponsored by MediciNova.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04054206 is a Phase 1 study that has completed, run by MediciNova. The registered enrollment target is 12 participants.
The verdict
NCT04054206, a Phase 1 study, has completed, sponsored by MediciNova.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will investigate the PK, relative bioavailability, safety, and tolerability of the extended release (ER) 50 mg MN-166 (ibudilast) tablet formulation as compared to the intermediate-release (IR) capsule formulation of MN-166 (ibudilast) and to examine the effect of food on the pharmacokinetics of the ER formulation.
Interventions
- DRUG MN-166
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2020-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04054206
The ClinicalTrials.gov registry entry for NCT04054206 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediciNova, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MN-166 is the first listed.
NCT04054206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04054206 about?
NCT04054206 is a clinical study titled "Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers". This study will investigate the PK, relative bioavailability, safety, and tolerability of the extended release (ER) 50 mg MN-166 (ibudilast) tablet formulation as compared to the intermediate-release (IR) capsule formulation of MN-166 (ibudilast) and to examine the effect of food on the pharmacokine...
What is the current status of trial NCT04054206?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-06-24. Estimated completion is 2020-05-31.
What interventions are being tested in trial NCT04054206?
The interventions under investigation include: MN-166 (DRUG).
Who is sponsoring clinical trial NCT04054206?
This trial is sponsored by MediciNova, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.